Real-World Evidence in Cost-Effectiveness Analysis of Enhanced Influenza Vaccines in Adults ≥ 65 Years of Age: Literature Review and Expert Opinion

Influenza vaccination can benefit most populations, including adults ≥ 65 years of age, who are at greater risk of influenza-related complications. In many countries, enhanced vaccines, such as adjuvanted, high-dose, and recombinant trivalent/quadrivalent influenza vaccines (aTIV/aQIV, HD-TIV/HD-QIV...

Descripción completa

Detalles Bibliográficos
Autores principales: Postma, Maarten, Fisman, David, Giglio, Norberto, Márquez-Peláez, Sergio, Nguyen, Van Hung, Pugliese, Andrea, Ruiz-Aragón, Jesús, Urueña, Analia, Mould-Quevedo, Joaquin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302365/
https://www.ncbi.nlm.nih.gov/pubmed/37376478
http://dx.doi.org/10.3390/vaccines11061089

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302365/
https://www.ncbi.nlm.nih.gov/pubmed/37376478
http://dx.doi.org/10.3390/vaccines11061089

Ejemplares similares